obesity drug glp-1 news today New oral delivers up to 12% weight loss in 36 weeks New Guidelines on GLP-1 Drugs

There are a number of methods to reduce the out-of-pocket cost of these drugs, including subsidies and increasing insurance coverage, but Govind Persad of the University of Colorado Law School noted that it is also critical to ensure that incentivesmany of which are monetaryremain for drug developers to continue to innovate in this field while simultaneously maximizing patient access now

Foundayo is approved for adults with obesity, or those who are overweight with at least one weight-related health condition, such as high blood pressure or high cholesterol

Note: Prices can vary depending on the pharmacy, location, and dosage

While recognized for its leadership in metabolic health, Pendulum is advancing broader applications of the microbiome to unlock new possibilities in preventive and therapeutic care

FDA Crackdown on Compounded GLP-1s (Regulatory): On February 6, 2026, the FDA announced a formal intent to restrict the use of active pharmaceutical ingredients (APIs) for non-approved compounded GLP-1 drugs, targeting "mass-marketed" alternatives from companies like Hims & Hers as the national supply of brand-name versions stabilized